Vivos OKd on Pediatric Sleep Apnea and Snoring Treatment

 Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model

Vivos’ DNA appliance now approved to reduce snoring and treat moderate to severe OSA in children aged 6 to 17

https://www.globenewswire.com/news-release/2024/09/18/2948068/0/en/Vivos-Therapeutics-Receives-Groundbreaking-FDA-510-k-Clearance-to-Treat-Moderate-to-Severe-Pediatric-Sleep-Apnea-and-Snoring.html